InspireMD : April 2026 Investor Deck

Published: 2026-04-14 13:30:10 ET NSPR

Published on 04/14/2026 at 01:30 pm EDT

April 2026

Dedicated to advancing the prevention of stroke and treatment of carotid artery disease

MicroNet Mesh-Covered Protection

SmartFit Technology

Deep industry experience and subject matter expertise

Marvin Slosman

Chief Executive Officer

30+ years of medical device

experience, NSPR since 2019

Previous CEO/President of ITAMAR Medical, Ovalum Vascular, Phormax Medical

Prior experience at JNJ, GE Healthcare and Baxter

BS from University of Alabama, MBA from University of Chicago

Shane Gleason

Chief Commercial Officer

20+ years of cardiovascular medical

device experience, NSPR since 2023

Previous CCO of Nuvaira; VP Sales of TriVascular, Cordis and Surmodics

Prior experience at Abbott and Edwards Lifesciences

BS in Engineering Science and Mechanics from Virginia Tech, MBA from University of Maryland

Mike Lawless

Chief Financial Officer

20+ years of financial management, NSPR since 2025

Prior CFO of Lifeward Ltd. and Brooks Life Sciences

Previous leadership experience at Brooks Automation, PerkinElmer, MFS Investment Management

BA in Economics from Swarthmore College, MBA from Tuck School of Business at Dartmouth College

CAROTID ARTERY DISEASE

MicroNetTM covered CGuard® stent platform could become the new gold standard

CEREBRAL ANEURYSMS

CORONARY ARTERY DISEASE

THORACIC/ABDOMINAL AORTIC ANEURYSMS

PERIPHERAL ARTERIAL DISEASE

70% Endo1 77% Endo2 65% Endo3 81% Endo4

35%

45%Endo

>12% CAGR5

70% Endo

Oth 3

2025 2030

Already have been converted to endovascular-first procedures

Converting to endo

1 Bekelis K, Gottlieb DJ, Su Y, et al. Comparison of clipping and coiling in elderly patients with unruptured cerebral aneurysms. J Neurosurg. 2017;126(3):811-818

2 Culler SD, Kugelmass AD, Brown PP, , et al. Trends in Coronary Revascularization Procedures Among Medicare Beneficiaries Between 2008 and 2012. Circulation. 2015;131(4):362-70

3 Beck AW, Sedrakyan A, Mao J, et al. Variations in Abdominal Aortic Aneurysm Care: A Report From the International Consortium of Vascular Registries. Circulation. 2016;134(24):1948-1958

4 Guez, D., Hansberry, D. R., Gonsalves, C. F., Eschelman, D. J., Parker, L., Rao, V. M., & Levin, D. C. Recent Trends in Endovascular and Surgical Treatment of Peripheral Arterial Disease in the Medicare Population. AJR Am J

Roentgenol. 2020 May;214(5):962-966. 5

5. Based on claims data, AcuityMD

CAS/TCAR continues to gain over CEA

US Market Size

30,000

CEA CAS/TCAR

$207

$113

$150

$207

$277

$460

$296

$836M1

$987M

25,000

20,000

15,000

10,000

TCAR coverage

CAS coverage expansion

CREST-2

publication

5,000

expansion

2 3

2022

2023

2024

2025

2026

2027

DRG/CPT data by Facility and HCP

~151K annual carotid intervention claims

Accounts for ~90% of procedures (does not include Kaiser, Gov't/DoD)

12% stent (CAS + TCAR) CAGR over prior three years, modeled to increase to 13% post CREST-2

2025 2030

Stenting Procedure Mix: 50% CAS / 50% TCAR

Based on claims data, AcuityMD

Only ~10-15% of diagnosed patients treated annually

~160,000

35k

CAS

35k

TCAR

90k

CEA

Expanding Treatment Population

CMS coverage expansion broadens eligible treatment population

Annual U.S. Procedures

~1,000,000

Untreated U.S. Diagnosed Patients

2025

2030

~200,000

Annual U.S. Procedures

70k CAS

70k TCAR

60k CEA

Growth of Carotid Stenting

CREST-2 Validates Revascularization Benefits

Access to next generation solutions - CGuard Prime

de Weerd M. et al. Prevalence of asymptomatic carotid artery stenosis in the general population. Stroke. 2010;41:1294-1297.

Rockman CB. et al. Carotid artery disease: epidemiology and screening. Journal of Vascular Surgery. 2010.

Naylor AR. Management of asymptomatic carotid stenosis. Lancet Neurology. 2022;21:355-366.

Based on claims data, AcuityMD

Evidence. Policy. Platform. Team.

ENDOVASCULAR MARKET SHIFT

CMS Coverage Expanded

Standard Risk and Asymptomatic Reimbursement

Enables stent-first approach to carotid revascularization

Landmark Clinical Evidence

CREST-2 Validates Revascularization Benefit

Reinforces role of carotid stenting in the market

PLATFORM ADVANTAGE

CGuard® Carotid Stent Platform Proprietary MicroNet Technology Highly differentiated platform for treatment of carotid artery disease and stroke prevention

ORGANIZATIONAL READINESS

Unmatched Clinical Evidence Short and Long-Term Results

Ten clinical trials completed with >2,000 patients presented or published including US IDE trial

Deep Pipeline and Strategic Roadmap MicroNet technology pipeline; CGuard

Prime line extension and SwitchGuard NPS for TCAR; acute stroke with tandem lesions

High-Performance Team

Deep expertise in carotid and neuro intervention

Benefits are independent of access method

CAS

Transfemoral/ Transradial

We are positioned to capitalize on the ongoing paradigm shift toward a "stent first" approach and away from surgery

TCAR

Transcarotid

CGuard® Prime

Tandem Lesions

Stroke/Neuro

90% occlusion

Stenting

CGuard® Stent

Surgical Endarterectomy

CGuard Prime Dual Layer Design

CGuard Prime is designed to prevent embolization by securing carotid plaque behind its MicroNet mesh, preventing prolapse through the stent struts while maintaining blood flow to the external carotid artery.

CGuard Prime has the smallest pore size of any approved carotid stent (150-180 μm)*

CGuard

Conventional carotid stents vs CGuard® Prime dual layer design

Conventional Carotid Stent

Unmatched Foundational Data and Evidence

30-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials

CGUARDIANS 30-day outcomes

30-day DSMI (multiple FDA trials)

Intention to Treat

Per Protocol1,2

8.30%

4.80%

5.40%

5.80%

5.20%

5.10%

3.50%

2.30%

0.95%

30-day DSMI

0.95% (3)

0.63% (2)

Death

0.32% (1)

0.0% (0)

Stroke

0.95% (3)

0.63% (2)

0.00% (0)

0.0% (0)

SAPPHIRE ARCHeR MAVERIC BEACH PROTECT CREST- CAS (Standard

Risk)

CREST- CEA (Standard Risk)

ROADSTER PERFORMANCE 2 C-GUARDIANS

Demonstrates the lowest 30-day DSMI rates of any FDA approval/clearance trial for carotid intervention (CAS or TCAR)

Trial includes independent event adjudication

0.95% event rate consistent with 1.03% 30-day event rate from >1350 patients in peer-reviewed, published studies of real-world use, supporting the CGuard Stent as a front-line therapeutic option for carotid revascularization

Kaplan-Meier estimate for all 1-year endpoints

Per Protocol Analysis excludes 15 patients with Major Protocol Deviations

Yadav JS, et al, N Engl J Med 2004;351:1493-501. Gray WA, et al, J Vasc Surg. 2006 Aug;44(2):258-68. Higashida RT, et al, Stroke. 2010 Feb;41(2):e102-9. White CJ, et al, CCI 2006 Apr;67(4):503-12. Iyer SS, et al, J Am Coll Cardiol. 2008 Jan 29;51(4):427-34. Matsumura JS, et al, J Vasc Surg. 2012 Apr;55(4):968-976.e5. SSED Premarket Approval Application (PMA)

Number: P040012/SO34. Kwolek CJ, et al, J Vasc Surg. 2015 Nov;62(5):1227-34. W. Gray VIVA 2023 13

365-Day Death/Stroke/MI (DSMI) rates, compared to other carotid trials

CGUARDIANS 365-day

365-day (multiple FDA trials)

Intention to Treat

Per Protocol1,2

12.20%

Primary Endpoint: 30-day Death, Stroke, or MI + Ipsilateral Stroke between

31 and 365 days

1.93% (6)

1.70% (5)

0.98% (3)

1.01% (3)

9.60%

8.90%

7.10%

5.90%

6.60%

3.40%

2.80%

1.93%

Target Lesion Revascularization (TLR) through 365 days.

SAPPHIRE* ARCHeR MAVERIC BEACH PROTECT CREST CAS

(Standard Risk)

CREST CEA

(Standard Risk)

PERFORMANCE 2 C-GUARDIANS

Demonstrates the lowest primary endpoint event rates of any FDA approval/clearance trial for CAS

Trial includes independent event adjudication

1.93% event rate consistent with 1.99% 1-year event rate from >1100 patients in peer-reviewed, published studies of real-world use, supporting the CGuard Stent as a front-line therapeutic option for carotid revascularization

Kaplan-Meier estimate for all 1-year endpoints

Per Protocol Analysis excludes 15 patients with Major Protocol Deviations

SAPPHIRE one-year primary endpoint also included Death/MI from 31-365 days

976.e5. SSED Premarket Approval Application (PMA) Number: P040012/SO34. Kwolek CJ, et al, J Vasc Surg. 2015 Nov;62(5):1227-34. Langhof, LINC 2024 14

CGuard commercially available in Europe since 2015 (CE Mark)

Study

Year

DS 30-Day % (n)

DSMI 30-Day % (n)

CARENET

2015

0.0%(0)

PARADIGM

2016

101

0.0%(0)

CASANA

2017

1.22%(1)

WISSGOTT I

2017

0.0%(0)

IRONGUARD I

2018

200

2.50%(5)

WISSGOTT II

2019

0.0%(0)

IRONGUARD 2

2020

733

0.5%(4)

1.09%(8)

GREEK Study

2021

103

0.0%(0)

SIBERIA

2021

0.0%(0)

Total

1,359

0.80%(11)

1.03%(14)

1. Schofer, J. et al. JACC Cardiovasc. Interv. 2015; 2) Casana, R. et al. Eur. J. Vasc. Endovasc. 2017; 3) Musialek, P. et al. Interv. Cardiol. 2016

Wissgott, C. et al. Int. Soc. Endovasc. Spec. 2017; 5) Speziale, F. et al. EuroIntervention 2018; 6) Wissgott, C. et al. J Endovasc Ther. 2019

7. Sirignano, P et al. Cardiovascular Interventions 2020;8) Tigkiropoulos, K. et al. Journal of EndoTherapy 2021; 9) Karpenko, A. et al JACC Cardiovasc. Interv. 2021

30-day and 12-month event rates by stent type (random-effect model)

Improvements from second-generation stents (SGS) relative to first-generation stents (FGS), but important differences exist amongst the SGS

CGuard®'s MicroNet

drives improvement both in event reduction (due to improved scaffolding) and restenosis reduction (due to less metal burden)

Event

FGS

SGS

Terumo RoadSaver/ Casper

Gore

(not marketed)

CGuard

30-day Stroke [%]

3.01

0.60

0.50

2.89

0.54

(95% CI)

(2.63-3.38)

(0.28-0.92)

(0.0-1.15)

(1.03-4.76)

(0.17-0.92)

30-day Death / Stroke / MI [%]

4.11

1.30

1.33

4.82

1.08

(95% CI)

(3.65-4.56)

(0.64-1.96)

(0.0-2.66)

(2.44-7.2)

(0.55-1.60)

12-month Ipsilateral Stroke [%]

3.51

0.7

0.26

3.1

0.38

(95% CI)

(2.52-4.50)

(0.0-1.47)

(0.0-1.27)

(1.11-5.1)

(0.0-0.9)

12-month Restenosis [%]

3.97

3.38

7.16

4.83

0.34

(95% CI)

(0.28-5.14)

(1.39-5.37)

(4.45-9.86)

(2.36-7.29)

(0.0-0.82)

12-month Ipsilateral Stroke / Restenosis [%] (95% CI)

8.15

(6.34-9.93)

5.12

(2.14-8.10)

7.86

(5.04-10.68)

7.93

(4.82-11.04)

0.73

(0.0-1.44)

1. Clinical Outcomes of Second- versus First-Generation Carotid Stents: A Systematic Review and Meta-Analysis, J. Clin. Med. 2022, 11

Any Perioperative Stroke or Death Plus Ipsilateral Stroke Thereafter up to 4 Years

Med Alone 6.0%

CAS + Med 2.8%

A Systematic Review and Meta-Analysis, J. Clin. Med. 2022, 11

Stroke and death (S/D) out to 4-years was 6.0% for medical therapy and 2.8% when CAS was added

Absolute difference of 3.2% favoring CAS was significant

Only 31 people with high-grade asymptomatic carotid stenosis needed to be treated to prevent a primary event at 4 years

Note- No primary events happened on the day of the procedure- what is left behind matters!

S/D out to 4-years was 5.3% for medical therapy and 3.7% when CEA was added

Absolute difference of 1.6% favoring CEA was not significant

1. Clinical Outcomes of Second- versus First-Generation Carotid Stents:

TCAR

InspireMD Combines SwitchGuard NPS with Best-in-Class CGuard® Implant

1. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic carotid stenoses for optimized endovascular lumen reconstruction and improved peri- and post-procedural outcomes, Advances in Interventional Cardiology 2020;16, 4 (62):495-506

Commercial and Corporate

Disclaimer

InspireMD Inc. published this content on April 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 14, 2026 at 17:29 UTC.